(αR，βS)-α-(4-羟基苯基)-β-甲基-4-(苯基甲基)-1-哌啶丙醇马来酸酯 | 1312991-76-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: (αR，βS)-α-(4-羟基苯基)-β-甲基-4-(苯基甲基)-1-哌啶丙醇马来酸酯
• 英文名称: Ro 25-6981 maleate
• 英文别名: 4-[(1R,2S)-3-(4-benzylpiperidin-1-yl)-1-hydroxy-2-methylpropyl]phenol;(Z)-but-2-enedioic acid
• CAS: 1312991-76-6
• 化学式: C26H33NO6
• 分子量: 455.5
• InChiKey: FYJZEHCQSUBZDY-SEELMCCHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.73
• 重原子数：
  33
• 可旋转键数：
  8
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  118
• 氢给体数：
  4
• 氢受体数：
  7

文献信息

• DRUG SCREENING PLATFORM FOR RETT SYNDROME
  申请人：THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

  公开号：US20150119327A1

  公开（公告）日：2015-04-30

  The invention provides a method for restoring a neural cell having a deficiency or alteration in glutamatergic pathway affecting neuron and/or glial function comprising contacting the cell with a NMDA receptor antagonist(s) and/or modulator(s) of a glutamatergic pathway, thereby restoring the neural cell having a deficiency or alteration in glutamatergic pathways affecting neuron and/or glial function.
• POLYSIALIC ACID AND DERIVATIVES THEREOF, PHARMACEUTICAL COMPOSITION AND METHOD OF PRODUCING POLYSIALIC ACID
  申请人：Medizinische Hochschule Hannover (MHH)

  公开号：US20210301038A1

  公开（公告）日：2021-09-30

  The present invention relates to a polysialic acid according to the general formula (1) as given as follows and derivatives thereof: (α(2→8)Neu5Ac) n , with n being an integer in the range from 6 to 13, for use in the prevention or treatment of neurological and neuropsychiatric disorders. The present invention also relates to a pharmaceutical composition comprising as an active ingredient said polysialic acid and/or derivatives and/or pharmaceutically acceptable salts thereof. Furthermore, the present invention relates to a method of producing said polysialic acid and/or pharmaceutically acceptable salts thereof.